SCHEMBL17147656

SCHEMBL17147656

O=C1Cc2ccc(C(=O)CO)cc2N1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.54
HDAC6 Q9UBN7 1/20 0.53
AHR P35869 3/20 0.51
CMA1 P23946 2/20 0.51
SMYD3 Q9H7B4 4/20 0.51
EIF2AK2 P19525 1/20 0.50
PDK2 Q15119 1/20 0.49
EPHX2 P34913 2/20 0.47
TDP2 O95551 2/20 0.45
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HSD11B1 P28845 2/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
HTR7 P34969 1/20 0.42
DRD3 P35462 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5479280 0.86 ALDH1A1 (0.59) CRBNHDAC6AHRCMA1SMYD3
SCHEMBL10626074 0.84 CRBN (0.55) CRBNHDAC6AHRCMA1SMYD3
Hydrochloric Acid SCHEMBL6992917 0.84 SMYD3 (0.52) CRBNHDAC6AHRCMA1SMYD3
SCHEMBL12694461 0.82 AHR (0.50) CRBNHDAC6AHRCMA1SMYD3
SCHEMBL398818 0.81 TDP2 (0.66) CRBNHDAC6AHRCMA1SMYD3
SCHEMBL3194345 0.81 SMYD3 (0.58) CRBNHDAC6AHRCMA1SMYD3
SCHEMBL30760741 0.81 SMYD3 (0.58) CRBNHDAC6AHRCMA1SMYD3
SCHEMBL29713338 0.81 TDP2 (0.66) CRBNHDAC6AHRCMA1SMYD3
SCHEMBL24124675 0.80 AHR (0.59) CRBNHDAC6AHRCMA1SMYD3
SCHEMBL14521036 0.80 CRBN (0.60) CRBNHDAC6AHRCMA1SMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160257648-A1 OXINDOLE INHIBITORS OF TYROSINE KINASE AUSPEX PHARMACEUTICALS, INC. 2016-09-08 US disclosed
US-20150284327-A1 OXINDOLE INHIBITORS OF TYROSINE KINASE AUSPEX PHARMACEUTICALS, INC. (US) 2015-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284327-A1 OXINDOLE INHIBITORS OF TYROSINE KINASE ABL1, ERBB2, LCK CRBN 800/4885HDAC6 901/4885AHR 1107/4885
US-20160257648-A1 OXINDOLE INHIBITORS OF TYROSINE KINASE ABL1, ERBB2, LCK CRBN 800/4885HDAC6 901/4885AHR 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.